Medline (MDLN) Holds Near $36–37 Range as Revenue Climbs but Profits Face Pressure
Key Takeaways
- Medline shares have been roughly flat over the trailing 30 days, holding near the $36–37 range after a volatile summer that saw the stock slide from its early-August highs.
- Second-quarter 2026 revenue rose 11.6% year over year to $7.7 billion, while net income fell 58.3% amid tariff headwinds and higher operating costs.
- Management raised full-year organic sales growth guidance to 9%–10% but lowered its adjusted EBITDA outlook to $3.3–$3.4 billion, underscoring persistent margin pressure.
- Multiple sell-side firms trimmed price targets following the Q2 report, while the broader analyst consensus remains a Buy with a 12-month target near $44.62.
- Regulatory scrutiny, including two FDA warning letters and an ongoing securities investigation, remains a key overhang on investor sentiment.
Where MDLN Stands in the Market Right Now
MDLN has traded in a relatively narrow band over the past 30 days, hovering in the mid-$30s after a sharp drawdown in early August pulled shares from above $42 to the low-$30s. The stock has since stabilized and recovered modestly, though it remains well below its post-IPO high of $50.88 and down year to date. With a market capitalization of roughly $48 billion and an average daily volume in the millions of shares, Medline is one of the more closely watched names in the healthcare supplies sector, yet its shares continue to reflect investor concerns about profitability rather than revenue momentum. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Understanding Medline’s Operations and Market Position
Medline is the largest provider of medical-surgical products and supply chain solutions in the United States, generating more than 90% of its revenue domestically while serving some of the country's largest health systems. The company operates through two segments: Medline Brand, which procures and manufactures products across surgical solutions, front-line care, and laboratory and diagnostics, and Supply Chain Solutions, which distributes third-party national-brand products and offers logistics and optimization services.
Founded in 1966 and headquartered in Northfield, Illinois, Medline offers approximately 190,000 Medline-branded products across more than 250 product families, alongside roughly 150,000 third-party products sourced from more than 1,250 vendors. Its scale is reinforced by more than 30 manufacturing facilities and a fleet of more than 2,000 owned delivery trucks, supporting prime vendor relationships that make the company a consolidated logistics partner for many customers. Medline completed its initial public offering on the Nasdaq in December 2025, and investors follow the stock for its exposure to defensive, recurring healthcare demand as well as its efforts to navigate cost inflation and tariff exposure.
What Drove Recent Moves in MDLN Shares
Medline's second-quarter 2026 results, reported in early August, captured the tension between top-line strength and bottom-line pressure that has defined the stock's recent trading. Net sales climbed 11.6% to $7.7 billion, and adjusted EBITDA rose 13.4% to $1.1 billion, but net income dropped 58.3% to $139 million as tariff costs, inflation, and operational investments weighed on profitability. Adjusted EPS of $0.50 exceeded consensus estimates of $0.32.
Management raised its full-year organic sales growth outlook to 9%–10%, up from a prior 8.5%–9.5%, citing strong demand and new customer wins. At the same time, the company reduced its adjusted EBITDA guidance to $3.3–$3.4 billion from $3.5–$3.6 billion, reflecting inflation, costs tied to the Tracy fire, and planned operational investments.
In response, numerous analysts lowered their price targets while largely maintaining constructive ratings. JPMorgan, TD Cowen, Morgan Stanley, and BMO Capital were among the firms trimming targets, with the consensus price target settling near $44.62. The stock has also contended with negative catalysts, including two FDA warning letters issued within a two-month span over quality lapses and a securities investigation announced by Kaplan Fox & Kilsheimer LLP. A regulatory filing disclosed that GIC Private Ltd, a holder of more than 10% of shares, sold 1.5 million shares in mid-August, adding to supply-related pressure. From what I see, these regulatory and institutional moves warrant close attention.
2026 Outlook and What Investors Should Watch
Heading into the remainder of 2026, Medline's trajectory will likely hinge on its ability to defend margins while sustaining high-single-digit organic sales growth. Key areas to monitor include the evolution of tariff and inflation costs, the financial impact and remediation timeline associated with the FDA warning letters and the ongoing securities investigation, and any further updates to full-year adjusted EBITDA guidance.
Investors should also watch demand trends across the healthcare provider landscape, the pace of new customer wins and prime vendor relationships, and management's cost-saving initiatives aimed at offsetting margin erosion. Competitive dynamics within medical-surgical distribution and the potential for further institutional share movements following the GIC sale round out the factors that could shape sentiment in the months ahead. I’m watching this closely as the company works through these issues.
Integrating AI Tools Into My Research Process
When evaluating names like MDLN, I often turn to Tickeron’s AI Trading Bots to test different systematic approaches alongside my own fundamental review. The platform surfaces a range of strategies that can help compare short-term signals with longer-term trend ideas, which adds another layer to how I assess risk and opportunity in the healthcare sector. It is one way I try to stay disciplined when volatility or regulatory news creates uncertainty.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
MDLN sees MACD Histogram just turned negative
MDLN saw its Moving Average Convergence Divergence Histogram (MACD) turn negative on September 10, 2026. This is a bearish signal that suggests the stock could decline going forward. Tickeron's A.I.dvisor looked at 5 instances where the indicator turned negative. In 5 of the 5 cases the stock moved lower in the days that followed. This puts the odds of a downward move at 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on September 08, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on MDLN as a result. In 7 of 8 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 88%.
The 10-day moving average for MDLN crossed bearishly below the 50-day moving average on August 11, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 1 of 2 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 50%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where MDLN declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 72%.
The Aroon Indicator for MDLN entered a downward trend on August 12, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.
Following a +4.21% 3-day Advance, the price is estimated to grow further. Considering data from situations where MDLN advanced for three days, in 31 of 40 cases, the price rose further within the following month. The odds of a continued upward trend are 77%.
MDLN may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 11 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 55 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.467) is normal, around the industry mean (4.965). P/E Ratio (40.710) is within average values for comparable stocks, (142.488). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (3.236). Dividend Yield (0.000) settles around the average of (0.015) among similar stocks. P/S Ratio (0.953) is also within normal values, averaging (74.759).
The Tickeron SMR rating for this company is 64 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Price Growth Rating for this company is 72 (best 1 - 100 worst), indicating slightly worse than average price growth. MDLN’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. MDLN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 96, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry PharmaceuticalsOther